Astria Therapeutics Inc ATXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATXS is a good fit for your portfolio.
News
-
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
-
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
-
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
-
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
-
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $9.80
- Day Range
- $9.51–9.97
- 52-Week Range
- $4.26–16.90
- Bid/Ask
- $9.53 / $9.99
- Market Cap
- $529.27 Mil
- Volume/Avg
- 748,168 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 59
- Website
- https://www.astriatx.com
Comparables
Valuation
|
Metric
|
ATXS
|
VRDN
|
CELC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.93 | 3.27 | 3.15 |
Price/Sales | — | 2,031.07 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ATXS
VRDN
CELC
Financial Strength
|
Metric
|
ATXS
|
VRDN
|
CELC
|
|---|---|---|---|
Quick Ratio | 21.34 | 17.93 | 12.78 |
Current Ratio | 21.73 | 18.26 | 13.43 |
Interest Coverage | — | −137.76 | −12.43 |
Quick Ratio
ATXS
VRDN
CELC
Profitability
|
Metric
|
ATXS
|
VRDN
|
CELC
|
|---|---|---|---|
Return on Assets (Normalized) | −23.26% | −42.76% | −35.57% |
Return on Equity (Normalized) | −44.07% | −82.42% | −49.08% |
Return on Invested Capital (Normalized) | −28.94% | −50.70% | −39.21% |
Return on Assets
ATXS
VRDN
CELC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gspzssqj | Gbn | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gwtbzxb | Plpwgvn | $104.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pxvwbpynr | Yzcwvn | $98.8 Bil | |
MRNA
| Moderna Inc | Zzvrrjqz | Ncbg | $38.8 Bil | |
ARGX
| argenx SE ADR | Qkbfwbt | Fdw | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Gpsfgxrj | Nnkd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lqqmbqvfm | Mwtmgt | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qkdlrzh | Zpcjsw | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Shrnnzcch | Gcfhbk | $12.4 Bil | |
INCY
| Incyte Corp | Dtpthmgr | Vxxgh | $11.9 Bil |